Friday, 16 Nov 2018

You are here

Biosimilar Pricing Wars Have Begun

This week Merck announched the US launch of its biosimilar to infliximab, and announced it will discount 35% to the branded version's wholesale acquisition cost. This comes in stark contrast to Pfizer's Inflectra, another infliximab biosimilar, that was lauched with a disappointing 15% discount. Disappointing to those expecting greater savings with biosimilars being newly launched.

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Merck has priced Renflexis at a deeper discount to Remicade (Janssen) and Inflectra (Pfizer). Renflexis will have an introductory wholesale acquisition cost (WAC) of $753.39. The WAC of Remicade was $1,167.82 and Inflectra (infliximab-dyyb) was $946.28 according to Red Book July 24.  WACs do not include discounts that may be paid on the products.

Renflexis was developed by Samsung Bioepis and is being marketed by Merck in the U.S. Renflexis was approved by the FDA on April 21 for the following indications:  Crohn's, pediatric Crohn's disease, rheumatoid arthritis, psorisis, psoriatic arthritis and ankylosing spondylitis.

Sales of Remicade did drop 14% year over year in the second quarter, but J&J chalked much of that decline up to the roughly $170 million in rebate adjustments in the same period last year.

The pricing schemes are unknown for the biosimilars to follow, including Sandoz's Erelzi (etanercept) and Amgen's Amjevita (adalimumab). 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

TNF Inhibitors Don't Increase Cancer Risk in Children

While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population.